YPOG advises Venrock Healthcare Capital Partners on second closing of Tubulis $401 million Series C one of Europe's largest private biotech financings

YPOG advised lead investor Venrock Healthcare Capital Partners on the second closing of Tubulis' Series C financing, in close cooperation with US law firm Cooley LLP. The second closing increased the total volume of the Series C to €344 million (USD 401 million), making it one of the largest private financings in European biotech history. The investor group at the second closing expanded to include new investors Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing. Participants in the first closing included Wellington Management, Ascenta Capital and existing investors Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, HTGF, OCCIDENT and Seventure Partners. The additional funds will be used to accelerate the clinical development of Tubulis' lead candidate TUB-040, in particular to prepare pivotal Phase III clinical trials relevant for regulatory approval. TUB-040 targets the tumor antigen NaPi2b, which is often highly expressed in ovarian cancer and other solid tumors; Tubulis presented first positive clinical data from its ongoing Phase I/IIa study at this year’s ESMO Congress in Berlin. Capital will also be invested in the expansion of Tubulis' proprietary ADC (antibody-drug conjugate) technology platforms. These systems combine targeted antibodies with potent cytotoxic payloads to attack tumor cells while sparing healthy tissue. The financing will support development of new drug components, combination therapies and the expansion of the company’s clinical and preclinical pipeline. YPOG represented client(s) Venrock Healthcare Capital Partners with a team composed by: Dr. Benjamin Ullrich (Lead, Transactions), Partner, Berlin; Stefan Richter (Tax), Partner, Hamburg; Dr. Benedikt Flöter (IP/IT/Data Protection), Partner, Berlin; Dr. Carolin Raspé (Corporate Crime + Compliance + Investigations), Partner, Munich; Dr. Emma Peters (Transactions), Associated Partner, Berlin; Tobias Lovett (Transactions), Associated Partner, Berlin; Pia Meven (Transactions), Associated Partner, Berlin; Anna Eickmeier (IP/IT/Data Protection), Senior Associate, Berlin; Theresia M.R. Heinrich (Transactions), Senior Associate, Berlin; Konstantina Nathanail (IP/IT/Data Protection), Associate, Berlin; Silke Ricken (Corporate), Associate, Berlin; Dr. Christian Busmann (Tax), Associate, Hamburg. Cooley LLP represented client(s) Venrock Healthcare Capital Partners in cooperation with YPOG with a team composed by: James Schneider (Partner, Boston).

YPOG advises Venrock Healthcare Capital Partners on second closing of Tubulis $401 million Series C one of Europe's largest private biotech financings

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads